TY - JOUR
T1 - Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
AU - Evans, Douglas B.
AU - Varadhachary, Gauri R.
AU - Crane, Christopher H.
AU - Sun, Charlotte C.
AU - Lee, Jeffrey E.
AU - Pisters, Peter W.T.
AU - Vauthey, Jean Nicolas
AU - Wang, Huamin
AU - Cleary, Karen R.
AU - Staerkel, Gregg A.
AU - Charnsangavej, Chusilp
AU - Lano, Elizabeth A.
AU - Ho, Linus
AU - Lenzi, Renato
AU - Abbruzzese, James L.
AU - Wolff, Robert A.
PY - 2008
Y1 - 2008
N2 - Purpose: We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma. Patients and Methods: Eligible patients with pancreatic head/uncinate process adenocarcinoma and radiographically defined potentially resectable disease received chemoradiation with 7 weekly intravenous (IV) infusions of gemcitabine (400 mg/m2 IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions over 2 weeks). Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery. Results: The study enrolled 86 patients. At the time of restaging, disease progression or a decline in performance status precluded 13 patients from surgery. Seventy-three (85%) of 86 patients were taken to surgery, extrapancreatic disease was found in nine, and 64 (74%) of 86 underwent a successful PD. Median overall survival (86 patients) was 22.7 months with a 27% 5-year survival. Median survival was 34 months for the 64 patients who underwent PD and 7 months for the 22 unresected patients (P < .001). The 5-year survival for those who did and did not undergo PD was 36% and 0%, respectively. Conclusion: Preoperative gemcitabine-based chemoradiation followed by restaging and evaluation for surgery separated the study population into two different subsets: patients likely to benefit from PD (n = 64) and those in whom surgery would be unlikely to provide clinical benefit (n = 22). Furthermore, the encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.
AB - Purpose: We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma. Patients and Methods: Eligible patients with pancreatic head/uncinate process adenocarcinoma and radiographically defined potentially resectable disease received chemoradiation with 7 weekly intravenous (IV) infusions of gemcitabine (400 mg/m2 IV over 30 minutes) plus radiation therapy (30 Gy in 10 fractions over 2 weeks). Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery. Results: The study enrolled 86 patients. At the time of restaging, disease progression or a decline in performance status precluded 13 patients from surgery. Seventy-three (85%) of 86 patients were taken to surgery, extrapancreatic disease was found in nine, and 64 (74%) of 86 underwent a successful PD. Median overall survival (86 patients) was 22.7 months with a 27% 5-year survival. Median survival was 34 months for the 64 patients who underwent PD and 7 months for the 22 unresected patients (P < .001). The 5-year survival for those who did and did not undergo PD was 36% and 0%, respectively. Conclusion: Preoperative gemcitabine-based chemoradiation followed by restaging and evaluation for surgery separated the study population into two different subsets: patients likely to benefit from PD (n = 64) and those in whom surgery would be unlikely to provide clinical benefit (n = 22). Furthermore, the encouraging overall survival observed in this large trial supports the continued investigation of gemcitabine-based preoperative therapy in resectable pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=49049101358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=49049101358&partnerID=8YFLogxK
U2 - 10.1200/JCO.2007.15.8634
DO - 10.1200/JCO.2007.15.8634
M3 - Article
C2 - 18640930
AN - SCOPUS:49049101358
SN - 0732-183X
VL - 26
SP - 3496
EP - 3502
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 21
ER -